Physician profile
Christopher E Byard
NPI 1730173535
$5,440.61
in general payments reported to CMS, 2019-2025
26 companies · $14.59 in 2025
The $14.59 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $820 · 2021: $672 · 2022: $1,006 · 2023: $913 · 2024: $1,252 · 2025: $14.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $789.72 | 2019-2024 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $637.70 | 2019-2025 | |
| Amarin Pharma, INC. | $634.50 | 2019-2023 | |
| Pfizer INC. | $559.09 | 2019-2024 | |
| Amgen INC. | $545.29 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $444.69 | 2019-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $302.10 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.40 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $195.97 | 2021-2024 | Verquvo |
| Philips North America LLC | $189.16 | 2020-2024 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.95 | 2019-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $153.74 | 2020-2024 | |
| Esperion Therapeutics, INC. | $116.67 | 2022-2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $75.93 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $52.09 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $43.10 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $42.29 | 2022-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $33.81 | 2024 | Arcalyst |
| Chiesi USA, INC. | $29.75 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $23.49 | 2019-2020 | |
| Abbott Laboratories | $22.92 | 2023 | Confirm Rx |
| Lantheus Medical Imaging, INC. | $21.72 | 2024 | |
| Medtronic, INC. | $21.17 | 2024 | Micra |
| Abiomed | $19.87 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $17.03 | 2019-2020 | |
| Scpharmaceuticals INC. | $16.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Byard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.